Lymphatic metastasis is facilitated by lymphangiogenic growth factor vascular endothelial growth factor-C (VEGFC) that is secreted by some primary tumors. We previously identified tumor necrosis factor superfamily 15 (TNFSF15), a blood vascular endothelium-derived cytokine, in lymphatic endothelial cells, as a key molecular modulator during lymphangiogenesis. However, the effect of TNFSF15 on tumor lymphatic metastasis and the underlying molecular mechanisms remain unclear. We report here that TNFSF15, which is known to inhibit primary tumor growth by sup- 
| INTRODUCTION
Metastasis is the major cause of death in cancer patients, including lung cancer, 1, 2 and the spread of tumor cells to lymph nodes has been the main negative prognostic factor for lung cancer. 3, 4 Lymphatic metastasis is considered a major route for cancer cell dissemination, 4, 5 and the spreading of tumor cells to lymph nodes is a common lymphatic-mediated metastasis pattern for carcinomas, draining either through preexisting lymphatic vessels or via the newly formed lymphatic capillaries. 6, 7 However, the pathobiology for lymphatic metastasis has remained unclear. Recent studies have
shown that some tumors secrete lymphangiogenic growth factors, including vascular endothelial growth factor-C (VEGFC) and vascular endothelial growth factor-D (VEGFD), which act on the lymphatic vasculature to facilitate metastasis. [8] [9] [10] [11] In addition, other molecules/ substances, such as sine oculis homeobox homolog 1 (SIX1) 9 in breast cancer, lipopolysaccharide (LPS) 10 in colorectal cancer and high-mobility group box 1 protein (HMGB1) 12 in colon cancer, can all promote lymphatic metastasis by increasing VEGFC expression.
However, although VEGFC and VEGFD have been identified as the main signal factors for driving lymphangiogenesis, the mechanism by which VEGFC or VEGFD is regulated in lung cancer is not clear. Further elucidation of the pathogenesis of lymphatic metastasis in lung cancer would represent a critical step forward for improving therapeutic strategies.
The tumor necrosis factor superfamily member TNFSF15 (also known as TL1A or VEGI), a cytokine produced predominantly by blood endothelial cells (BEC) in established blood vessels, is a specific inhibitor of BEC proliferation, being able to arrest growth in quiescent BEC but also to induce apoptosis in proliferating BEC.
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TNFSF15 inhibits angiogenesis by down-modulating VEGF receptor-1 activities in endothelia progenitor cells (EPC). 14 It also inhibits differentiation of Lin − -Sca-1 + EPC into BEC and incorporation of EPC into tumor vasculature in murine models. 15 TNFSF15 expression is high in the early stages, while is absent or marginal in the late stages in various cancers. [16] [17] [18] Indicating its importance in angiogenesis and cancer progression, systemic administration of TNFSF15 led to inhibition of tumor angiogenesis and growth. 19 Furthermore, using an embryonic lymphangiogenesis model, we recently demonstrated that TNFSF15 facilitated lymphangiogenesis through upregulation of VEGFR3 in lymphatic endothelial cells (LEC) in physiological conditions. 20 These studies suggested that TNFSF15 may participate in tumor metastasis in the early stages by prompting tumor lymphangiogenesis. However, whether TNFSF15 is involved in tumor lymphangiogenesis and tumor metastasis in lung cancer remains to be determined.
Therefore, in this study, we investigated the role of TNFSF15 in tumor metastasis, particularly in lymphangiogenesis and lymphatic metastasis, and attempted to explain the molecular mechanism of TNFSF15 in regulating VEGFC expression in lung cancer. We report here that TNFSF15 facilitates lymphatic metastasis in a mouse model of lung cancer by upregulating VEGFC expression in A549 human lung cancer cells and that this activity is mediated by death receptor 3 (DR3, also known as tumor necrosis factor receptor superfamily member 25 or TNFRSF25) and nuclear factor (NF)-κB signaling Figure S1 ). In brief, the EGFP-expressing lentivector (Control/EGFP) and lentivector-encoding TNFSF15
(TNFSF15/EGFP) were purchased from Genechem (Shanghai, China).
Prior to transfection, A549 cells were seeded in 6-well plates given by Professor Lu-yuan Li (Nankai University, Tianjin, China), which was prepared as previously described. 
| RNA interference
The siRNA for DR3 and NF-κB subunit p65 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). | 2471
shVEGFC and TNFSF15 CM were added to the media in the lower chambers. After 24-hour incubation, the inserts were rinsed, fixed in 2% paraformaldehyde for 10 minutes, and then stained with crystal violet (Beyotime, Haimen, Jiangsu, China). The numbers of cells that migrated per field were counted on 6 randomly chosen fields per well acquired at 200× magnification (ECLIPSE Ti, Nikon, Tokyo, Japan).
| Statistical analysis
The data were subjected to variance analysis (ANOVA), followed by 2-tailed, unpaired Student's t test. Differences with P-values <.05
were considered statistically significant. These experiments were repeated 2 times. Data are mean ± SD. ***P < .001; Student's t test podoplanin and VEGFC. We found that CD31 and VEGFA proteins were downregulated markedly in the TNFSF15 group when compared to the control group, and that, in sharp contrast, the TNFSF15 group showed higher podoplanin and VEGFC levels ( Figure 2A ).
Blood vessel densities (CD31 + ) on cross-sections of the primary tumors in the control group were more than 3 times those of the TNFSF15 group ( Figure 2B ). We determined VEGFA and VEGFC protein levels using a 4-step grading system (0, 1, 2 and 3 for negative, weak, strong and very strong staining, respectively). While VEGFA expression was high or very high in the control group, it was negative or low in the TNFSF15 group ( Figure 2C) . We obtained the opposite results for VEGFC expression ( Figure 2D ). Lymphatic vessel densities (podoplanin + ) were significantly higher in the TNFSF15 group than those in the control group, with the median values being 3 and 9 per field, respectively ( Figure 2E ). These findings indicate that TNFSF15 plays inverse roles in tumor angiogenesis and tumor lymphangiogenesis.
| Tumor necrosis factor superfamily 15 promotes lymphatic metastasis
Because tumor lymphangiogenesis provides an important route for lymphatic metastasis, we next determined whether the upregulation of VEGFR3 podoplanin and VEGFC under TNFSF15 can promote tumor lymph node metastasis. Autopsy analysis showed that most of the tumor-bearing mice in the TNFSF15 group developed metastatic lesions in inguinal lymph nodes, which were also much larger in volumes when compared to the control group ( Figure 3A,C) . Ki67, which is a proliferation marker, is used to present metastasis of human tumor cells as the anti-human Ki67 (ab92742) antibody does not cross-react with mouse Ki67. . C, VEGFA expression as quantified using a semiquantitative scoring system as described in the Materials and Methods. D, Average lymphatic vessel density as quantified by assessing the numbers of podoplanin-positively stained vessels in primary tumors of mice (n = 5 per group). E, VEGFA expression as quantified using a semiquantitative scoring system as described. Data are mean ± SD (n = 5). **P < .01, ***<.001 Student's t test. These experiments were performed 2 times QIN ET AL.
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( Figure 3D ). Collectively, these results provide compelling evidence that TNFSF15 is a positive regulator of lymphatic metastasis.
| Tumor necrosis factor superfamily 15
upregulates vascular endothelial growth factor-C expression in A549 lung cancer cells
We treated A549 cells with recombinant TNFSF15 (200 ng/mL, a concentration which was used previously to treat lymphatic endothelial cells) 20 and found that the treatment resulted in a considerable increase in VEGFC protein levels as determined by immunofluorescent staining ( Figure 4A ). Fluorescence intensity assessment revealed that VEGFC protein levels in TNFSF15-treated group were 4 times of that in vehicle-treated group ( Figure 4B ). In addition, we treated A549 cells with recombinant TNFSF15 (200 ng/mL) for 24 hours and found that the treatment resulted in a considerable increase in VEGFC protein levels as determined by western blotting analyses ( Figure 4C ).
We also found that DR3, the receptor that mediates TNFSF15 activities in ECs, was expressed in a high but constant level in A549 cells under the experimental conditions ( Figure 4C ). The increase in VEGFC level became apparent within 12 hours of TNFSF15 (200 ng/mL) treatment, reaching a level more than 2 times than that in vehicletreated cells within 24 hours ( Figure 4D ). Real-time PCR analyses revealed that TNFSF15 (200 ng/mL) treatment gave rise to a more than 2-fold increase in VEGFC mRNA within 3 hours ( Figure 4E ). Furthermore, we determined VEGFC concentration in the medium by ELISA and found that VEGFC levels under the TNFSF15 treatment were more than 4 times those in the vehicle-treated group ( Figure 4F ).
These data indicate that TNFSF15, which is predominantly expressed by vascular endothelial cells, is able to substantially stimulate VEGFC gene expression in A549 lung cancer cells.
| DR3/NF-κB signaling pathway is involved in
tumor necrosis factor superfamily 15-stimulated vascular endothelial growth factor-C production in A549 cells
To determine whether DR3 mediates upregulation of VEGFC in A549 cells, we treated A549 cells with scrambled or DR3 siRNA (40 pmol/mL, respectively) to silence the gene of DR3 and then treated with (or without) TNFSF15 (200 ng/mL). The DR3 siRNA treatment resulted in a >90% decline in DR3 protein levels, rendering a diminished ability of TNFSF15 to induce VEGFC protein expression ( Figure 5A ). Secretion of VEGFC is partly promoted by the NF-κB signaling pathway. 25 To find out whether this signaling pathway is involved in TNFSF15-stimulated VEGFC secretion by A549 cells, we treated the cells with PDTC (0.25 μmol/L), a known NF-κB inhibitor.
PDTC treatment led to an apparent reduction in TNFSF15-induced shVEGFC cell cultures for 72 hours, and the cell numbers were counted. We found that TNFSF15-treated cell medium led to a 1.5-fold enhancement of the proliferation rate of LEC and that this effect can also be blocked by VEGFC silencing ( Figure 6D ).
| DISCUSSION
Tumor necrosis factor superfamily 15, a cytokine secreted by endothelial cells, has important effects on anti-angiogenesis and prolymphangiogenesis. Previous studies have found that TNFSF15 can inhibit tumor growth via anti-angiogenesis. 17, 19, 26 In addition, the effect of TNFSF15 on lymphangiogenesis had also been studied under physiological conditions. 20 However, the role of TNFSF15 in tumor metastasis and the underlying mechanism remain unknown. Tumor necrosis factor superfamily 15 can inhibit angiogenesis and promote lymphangiogenesis in a mouse model of lung cancer.
Typically, both types of vessels grow or regress in parallel, which is consistent with our previous notion. In brief, the TNFSF15/DR3 signaling pathway may lead to different results, depending on the types of cells in which it is activated, and it leads to apoptosis in VEC and proliferation in LEC. 20 Tumor cell metastasis to regional lymph nodes is an early event in metastatic tumor spread and is frequently used as a prognostic factor for disease outcome. The existence and functionality of intratumoral lymphatics in human and experimental rodents remain controversial. Our findings indicate that TNFSF15-promoted lymphangiogenesis via upregulation of VEGFC in A549 cells provides portals for tumor metastasis, and the invasion of tumor cells into the lymphatic vessels is a critical step in metastasis. Given that TNFSF15
protein levels are highly expressed in the early stages (FIGO stages I and II) of cancer, 18 it would be meaningful to explore the potential correlation between TNFSF15 expression and occurrences of regional lymph node metastasis.
It has been affirmatively shown that DR3 works as the cell sur- Data are mean ± SD. ***P < .001; one-way ANOVA. These experiments were repeated 3 times F I G U R E 7 A schematic presentation of process involved in the lymphatic metastasis promoted by tumor necrosis factor superfamily 15 (TNFSF15). TNFSF15 binds to its receptor DR3 on A549 lung tumor cells, which subsequently causes activation of the NF-κB signaling pathway and secretion of vascular endothelial growth factor-C (VEGFC) by the A549 cells. VEGFC then promotes lymphangiogenesis and, consequently, lymphatic metastasis via the newly formed lymphatic vessels in primary tumors
